ATE240344T1 - Nor-pregnane zur induzierung hypothalamischer effekte - Google Patents

Nor-pregnane zur induzierung hypothalamischer effekte

Info

Publication number
ATE240344T1
ATE240344T1 AT96923241T AT96923241T ATE240344T1 AT E240344 T1 ATE240344 T1 AT E240344T1 AT 96923241 T AT96923241 T AT 96923241T AT 96923241 T AT96923241 T AT 96923241T AT E240344 T1 ATE240344 T1 AT E240344T1
Authority
AT
Austria
Prior art keywords
pregnanes
induce
hypothalamic effects
hypothalamic
effects
Prior art date
Application number
AT96923241T
Other languages
English (en)
Inventor
Clive L Jennings-White
David L Berliner
Nathan William Adams
Original Assignee
Pherin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherin Pharm Inc filed Critical Pherin Pharm Inc
Application granted granted Critical
Publication of ATE240344T1 publication Critical patent/ATE240344T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
AT96923241T 1995-06-07 1996-06-07 Nor-pregnane zur induzierung hypothalamischer effekte ATE240344T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/485,615 US5792757A (en) 1994-08-04 1995-06-07 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function
PCT/US1996/009665 WO1996040727A1 (en) 1995-06-07 1996-06-07 Novel nor-pregnanes for inducing hypothalamic effects

Publications (1)

Publication Number Publication Date
ATE240344T1 true ATE240344T1 (de) 2003-05-15

Family

ID=23928825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923241T ATE240344T1 (de) 1995-06-07 1996-06-07 Nor-pregnane zur induzierung hypothalamischer effekte

Country Status (17)

Country Link
US (3) US5792757A (de)
EP (1) EP0830369B1 (de)
JP (1) JPH11507360A (de)
KR (1) KR19990022640A (de)
CN (1) CN1191542A (de)
AT (1) ATE240344T1 (de)
AU (1) AU724787B2 (de)
BR (1) BR9609012A (de)
CA (1) CA2223397C (de)
CZ (1) CZ391597A3 (de)
DE (1) DE69628163T2 (de)
EA (1) EA000965B1 (de)
ES (1) ES2197949T3 (de)
HU (1) HUP9900887A3 (de)
NO (1) NO975709L (de)
NZ (1) NZ312303A (de)
WO (1) WO1996040727A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331534B1 (en) 1994-08-04 2001-12-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to alleviate pain
US6066627A (en) * 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
US6057439A (en) * 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US6117860A (en) * 1994-08-04 2000-09-12 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
US5922699A (en) * 1996-06-07 1999-07-13 Pherin Corporation 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
PL331357A1 (en) * 1996-07-23 1999-07-05 Pherin Pharmaceuticals Steroids as neurochemical vno stimulators for soothing the symptoms of premenstrual tension and anxiety
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
EP1832598A3 (de) 1999-09-30 2008-01-02 Hollis-Eden Pharmaceuticals Inc. Therapeutische Behandlung von androgenrezeptorbedingten Leiden
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US6555531B1 (en) * 1999-12-30 2003-04-29 Pherin Pharmaceuticals, Inc. Weight promoting composition, method, and product
US6413951B2 (en) * 2000-06-27 2002-07-02 Aventis Pharmaceuticals, Inc. 20-fluoro-17(20)-vinyl steroids
JP2004537506A (ja) 2001-03-01 2004-12-16 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症を治療するためのある種のステロイドの使用
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2004019953A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
EP2471536A1 (de) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroidanaloga sowie charakterisierungs- und behandlungsverfahren
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
WO2009039103A2 (en) * 2007-09-17 2009-03-26 Human Pheromone Sciences, Inc. Fragrance compositions and other compositions which contain naturally occurring substances found in corals
EP2278880B1 (de) 2008-04-09 2012-10-10 Pherin Pharmaceuticals, Inc. Steroidbehandlung für hitzewallungen
ES2728225T3 (es) 2009-02-20 2019-10-23 2 Bbb Medicines B V Sistema de administración de fármacos a base de glutatión
AU2010245823B2 (en) 2009-05-06 2016-11-24 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
LT3498725T (lt) * 2013-04-17 2021-09-27 Sage Therapeutics, Inc. Steroidas su 19-nor c3,3-dipakeistuoju c21-n-pirazolilu, skirtas naudoti terapijoje
SG11201702118YA (en) * 2014-09-17 2017-04-27 Prevacus Inc C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions
DE102020204506A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Weichspüler mit Pheromonen
DE102020204505A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Wasch-/Pflegeartikel umfassend Pheromone
DE102020204507A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Weichspüler mit aphrodisierend wirkenden Duftstoffen
DE102020204509A1 (de) 2020-04-07 2021-10-07 Henkel Ag & Co. Kgaa Waschmittel mit Pheromonen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL287863A (de)
US2840582A (en) * 1953-08-31 1958-06-24 Searle & Co Derivatives of 13-methyl-17-hydroxy-1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17-tetradecahydro-15h-cyclopenta[a]phenanthren-3-ones
DE1297603B (de) 1964-08-08 1969-06-19 Schering Ag Verfahren zur Herstellung von 3-Keto-delta 17(20)-pregnenen
ES319318A1 (es) 1964-11-13 1966-10-16 American Cyanamid Co Procedimiento para la preparaciën de una composiciën anticonceptiva
US3385849A (en) * 1965-07-01 1968-05-28 Hoffmann La Roche Process for the preparation of 17beta-pregnanes from 17-oxo-steroids
US3492318A (en) * 1968-01-22 1970-01-27 Syntex Corp Cyclopropenyl androstanes
US3682983A (en) * 1969-11-12 1972-08-08 Klaus Prezewowsky Preparation of {66 {11 {11 -17 ethinyl steroids
FR2097045A1 (en) 1970-07-30 1972-03-03 Roussel Uclaf 17-ethynylgon-4-en-3-ones - with progestomimetic activity useful as contraceptives and for gynaecological disorders
US3681410A (en) * 1970-08-07 1972-08-01 Syntex Corp Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
US5155045A (en) 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
JP2578369B2 (ja) * 1989-05-09 1997-02-05 ポーラ化成工業株式会社 芳香組成物
GB8912043D0 (en) * 1989-05-25 1989-07-12 Beecham Group Plc Novel compounds
US5272134A (en) * 1992-03-24 1993-12-21 Erox Corporation Fragrance compositions and other compositions which contain human pheromones
US5278141A (en) * 1992-03-24 1994-01-11 Erox Corporation Fragrance compositions containing human pheromones

Also Published As

Publication number Publication date
EP0830369A4 (de) 1999-06-09
EP0830369B1 (de) 2003-05-14
AU724787B2 (en) 2000-09-28
CA2223397C (en) 2007-07-31
BR9609012A (pt) 1999-12-14
EA000965B1 (ru) 2000-08-28
NZ312303A (en) 2000-01-28
US6242619B1 (en) 2001-06-05
JPH11507360A (ja) 1999-06-29
WO1996040727A1 (en) 1996-12-19
US5962443A (en) 1999-10-05
AU6380796A (en) 1996-12-30
CZ391597A3 (cs) 1998-06-17
HUP9900887A3 (en) 1999-11-29
CN1191542A (zh) 1998-08-26
EP0830369A1 (de) 1998-03-25
US5792757A (en) 1998-08-11
KR19990022640A (ko) 1999-03-25
NO975709D0 (no) 1997-12-05
HUP9900887A2 (hu) 1999-08-30
DE69628163D1 (de) 2003-06-18
ES2197949T3 (es) 2004-01-16
CA2223397A1 (en) 1996-12-19
NO975709L (no) 1998-02-05
MX9709693A (es) 1998-10-31
DE69628163T2 (de) 2004-04-01
EA199800052A1 (ru) 1998-08-27

Similar Documents

Publication Publication Date Title
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
MY115662A (en) Novel compounds with analgesic effect
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
EP0693924A4 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
IS4566A (is) Lyfjablanda til að gefa í gegnum húð
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
ATE108657T1 (de) Galanthemin enthaltende pharmazeutische formulierung zur behandlung des alkoholismus.
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
NO995127D0 (no) Stabiliserte tibolonblandinger
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
SE9504662D0 (sv) New compounds
DE69803670T2 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
ATE275953T1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
UA28539A (uk) Спосіб лікування хронічних запальних захворювань матки
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties